These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9000660)

  • 1. Endogenous interleukin 1 receptor antagonist during human bone marrow transplantation: increased levels during graft-versus-host disease, during infectious complications, and after immunoglobulin therapy.
    Schwaighofer H; Oberhuber G; Hebart H; Einsele H; Herold M; Nachbaur D; Eibl B; Tilg H; Kropshofer G; Ferrara JL; Niederwieser D
    Transplantation; 1997 Jan; 63(1):52-6. PubMed ID: 9000660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum cytokine levels after HLA-identical bone marrow transplantation.
    Liem LM; van Houwelingen HC; Goulmy E
    Transplantation; 1998 Oct; 66(7):863-71. PubMed ID: 9798695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.
    Antin JH; Weisdorf D; Neuberg D; Nicklow R; Clouthier S; Lee SJ; Alyea E; McGarigle C; Blazar BR; Sonis S; Soiffer RJ; Ferrara JL
    Blood; 2002 Nov; 100(10):3479-82. PubMed ID: 12393661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of interleukin 6, interleukin 8, and C-reactive protein after human allogeneic bone marrow transplantation.
    Schwaighofer H; Herold M; Schwarz T; Nordberg J; Ceska M; Prior C; Nachbaur D; Weyrer W; Brankova J; Eibl B
    Transplantation; 1994 Aug; 58(4):430-6. PubMed ID: 8073511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease.
    Sullivan KM
    Clin Exp Immunol; 1996 May; 104 Suppl 1():43-8. PubMed ID: 8625543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts.
    Feinstein LC; Seidel K; Jocum J; Bowden RA; Anasetti C; Deeg HJ; Flowers ME; Kansu E; Martin PJ; Nash RA; Storek J; Etzioni R; Applebaum FR; Hansen JA; Storb R; Sullivan KM
    Biol Blood Marrow Transplant; 1999; 5(6):369-78. PubMed ID: 10595814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation.
    Siadak MF; Kopecky K; Sullivan KM
    Clin Exp Immunol; 1994 Jul; 97 Suppl 1(Suppl 1):53-7. PubMed ID: 8033436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
    Kielsen K; Enevold C; Heilmann C; Sengeløv H; Pedersen AE; Ryder LP; Müller K
    Front Immunol; 2018; 9():109. PubMed ID: 29456530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels.
    Cottler-Fox M; Lynch M; Pickle LW; Cahill R; Spitzer TR; Deeg HJ
    Bone Marrow Transplant; 1991 Jul; 8(1):27-33. PubMed ID: 1655138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease.
    Antin JH; Weinstein HJ; Guinan EC; McCarthy P; Bierer BE; Gilliland DG; Parsons SK; Ballen KK; Rimm IJ; Falzarano G
    Blood; 1994 Aug; 84(4):1342-8. PubMed ID: 8049450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants.
    Cullup H; Dickinson AM; Jackson GH; Taylor PR; Cavet J; Middleton PG
    Br J Haematol; 2001 Jun; 113(3):807-13. PubMed ID: 11380474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 1 components in cicatricial pemphigoid. Role in intravenous immunoglobulin therapy.
    Kumari S; Bhol KC; Rehman F; Foster CS; Ahmed AR
    Cytokine; 2001 May; 14(4):218-24. PubMed ID: 11448121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
    Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J
    Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating interleukin-1 receptor antagonist (IL-1RA) serum levels in patients undergoing orthotopic heart transplantation.
    Thiele RI; Daniel V; Opelz G; Lange R; Sack FU; Jakob H; Hagl S
    Transpl Int; 1998; 11(6):443-8. PubMed ID: 9870274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.
    Sullivan KM; Storek J; Kopecky KJ; Jocom J; Longton G; Flowers M; Siadak M; Nims J; Witherspoon RP; Anasetti C; Appelbaum FR; Bowden RA; Buckner CD; Crawford SW; Deeg HJ; Hansen JA; McDonald GB; Sanders JE; Storb R
    Biol Blood Marrow Transplant; 1996 Feb; 2(1):44-53. PubMed ID: 9078354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG for intravenous use, autologous serum and plasma induce comparable interleukin-1 receptor antagonist liberation from human mononuclear cells: an in vitro phenomenon depending upon plastic adherence.
    Andersen LS; Petersen J; Svenson M; Bendtzen K
    Autoimmunity; 1995; 22(2):127-33. PubMed ID: 8722583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous immunoglobulin in bone marrow transplantation.
    Gale RP; Winston D
    Cancer; 1991 Sep; 68(6 Suppl):1451-3. PubMed ID: 1652350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum interleukin-12 levels in patients undergoing allogeneic or autologous bone marrow transplantation.
    Bonnotte B; Burdiles AM; Chehimi J; Carayol G; Pardoux C; Dietrich PY; Kubin M; Blay JY; Caignard A; Ibrahim A; Robinet E; Hayat M; Pico JL; Bourhis JH; Chouaib S
    Eur Cytokine Netw; 1996 Sep; 7(3):389-94. PubMed ID: 8954182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.